US-based clinical technology provider Medable has launched a comprehensive Partner Program designed to supply contract research organizations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities for digitally enabled studies. The program aims to reduce clinical trial timelines by at least 50%, delivering significant administrative and financial benefits to participating organizations.
AI-Powered Clinical Trial Acceleration
The Partner Program operates on Medable's established platform and is specifically designed to help CROs generate trial-specific quotes rapidly while enabling them to enter trial kick-off or bid defense meetings with pre-built digital studies. This capability represents a significant advancement in clinical trial preparation and execution efficiency.
The program offers CROs flexibility through three distinct support models: self-service, managed service, or a hybrid approach. This structure is designed to deliver higher margin services through the strategic implementation of generative AI technology.
Studio: Core AI Technology Platform
A key component of the Partner Program is access to Studio, Medable's AI-powered tool for creating, storing, and reusing eCOA instruments. Studio enables CROs to build eCOA assessments and deploy trials independently, providing the operational flexibility necessary to scale their operations effectively.
Studio's comprehensive feature set includes content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder. These tools are designed to streamline the trial development process while maintaining the precision required for clinical research applications.
Strategic Business Advantages
The program incorporates several features aimed at enhancing operational efficiency, including specialized tools for pricing, demo support for bid defense meetings, and a content library designed to facilitate reuse and scalability across multiple trials.
"We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process," said Alison Holland, Medable's chief customer officer. "Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start."
Company Background and Platform Reach
Based in California, Medable operates a digital clinical trials platform that has been utilized in nearly 400 trials across 70 countries to date. This extensive deployment demonstrates the company's established presence in the clinical technology sector and provides a foundation for the new Partner Program's implementation.
The company recently expanded its offerings with a digital-first long-term follow-up model specifically designed to reduce burdens on sites and participants in cell and gene therapy trials, indicating its continued focus on addressing specific challenges within specialized therapeutic areas.
